Based on clinical studies [35], MEK1/2 inhibitors received U.S. Food and Drug Administration (FDA) approval for tumors with activating BRAF mutations, including melanoma (trametinib, cobimetinib and binimetinib), non-small cell lung cancer (trametinib), and thyroid cancer (trametinib) (information available at https://www.fda.gov/ (accessed on 16 December 2020)). Here, MAP2K1 is linked to melanoma.